Fierce Healthcare
FEBRUARY 9, 2025
Behavioral health has lagged behind in the shift to value-based care, and a new paper from experts at Cigna outlines why these providers should consider making the switch, and the barriers they may face.
Pharmacy Times
FEBRUARY 9, 2025
These findings can lay the foundation for the development of machine learning models in chronic kidney disease (CKD) and kidney failure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 9, 2025
Top universities and medical centers stand to lose $100 million a year or more if a sweeping change to how the National Institutes of Health reimburses research costs takes effect on Monday. The big losers would include prestigious institutions in conservative states. NIH, the nation’s top funder of biomedical research, announced on Friday that it would substantially limit payments for indirect costs, administrative and facility expenses connected to research, starting almost immedi
Pharmacy Times
FEBRUARY 9, 2025
Molly Schiffer, PharmD, BCOP, discusses the logistical and operational challenges of delivering outpatient CAR T-cell therapy, emphasizing the benefits of outpatient treatment, including reduced costs, improved access to therapy, and better quality of life for patients.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Med Ed 101
FEBRUARY 9, 2025
This video is part of a three-part series covering new literature that could influence clinical practice. In this video, I discuss whether beta-blocker use post-MI is beneficial for patients with HFpEF. Background about the mechanism of action and typical place in therapy leads into background studies leading to the current research. Finally, the REDUCE-AMI study […] The post Beta-Blockers After MI and Use In HFpEF appeared first on Med Ed 101.
The Guardian - Pharmaceutical Industry
FEBRUARY 9, 2025
Billions in EU Covid funding have gone unaccounted for. By hiding its business behind personal messaging, Brussels is dodging public scrutiny For weeks during the height of the Covid pandemic in early 2021, the European Commission president, Ursula von der Leyen, personally exchanged calls and texts with Albert Bourla, the CEO of the pharmaceutical company Pfizer.
Expert insights. Personalized for you.
124 
Let's personalize your content